Table I. Positive numbers and rates for 30 antigens in various cohorts of serum samples.
| Autoantigens | PBC (n = 191) | Non-PBC (n = 321)a | Healthy (n = 50) | AIH (n = 43) | HBV (n = 55) | HCV (n = 31) | RA (n = 48) | SLE (n = 45) | SSc (n = 49) |
|---|---|---|---|---|---|---|---|---|---|
| M2 autoantigens | |||||||||
| BCOADC-E2 | 119 (62.3%) | 11 (3.4%) | 1 (2%) | 2 (4.7%) | 1 (1.8%) | 1 (3.2%) | 1 (2.1%) | 2 (4.4%) | 3 (6.1%) |
| PDC-E2 | 99 (51.8%) | 10 (3.1%) | 0 (0%) | 1 (2.3%) | 2 (3.6%) | 3 (9.7%) | 1 (2.1%) | 3 (6.7%) | 0 (0.0%) |
| OGDC-E2 | 16 (8.4%) | 6 (1.9%) | 0 (0%) | 0 (0.0%) | 1 (1.8%) | 0 (0.0%) | 1 (2.1%) | 2 (4.4%) | 2 (4.1%) |
| E3BP | 64 (33.5%) | 12 (3.7%) | 1 (2%) | 0 (0.0%) | 1 (1.8%) | 2 (6.5%) | 1 (2.1%) | 5 (11.1%) | 2 (4.1%) |
| PDC-E1β | 24 (12.6%) | 1 (0.3%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (2.0%) |
| PDC-E1α | 18 (9.4%) | 4 (1.2%) | 0 (0%) | 1 (2.3%) | 1 (1.8%) | 0 (0.0%) | 1 (2.1%) | 0 (0.0%) | 1 (2.0%) |
| Nuclear envelope autoantigens | |||||||||
| Gp210 | 112 (58.6%) | 20 (6.2%) | 0 (0%) | 4 (9.3%) | 2 (3.6%) | 2 (6.5%) | 4 (8.3%) | 6 (13.3%) | 2 (4.1%) |
| p62 | 14 (7.3%) | 5 (1.6%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 3 (6.7%) | 1 (2.0%) |
| LBR | 30 (15.7%) | 4 (1.2%) | 0 (0%) | 1 (2.3%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 2 (4.4%) | 0 (0.0%) |
| ACA autoantigen | |||||||||
| CENP-B | 59 (30.9%) | 19 (5.9%) | 0 (0%) | 6 (14.0%) | 0 (0.0%) | 4 (12.9%) | 2 (4.2%) | 1 (2.2%) | 6 (12.2%) |
| Multiple nuclear dots autoantigens | |||||||||
| Sp100 | 27 (14.1%) | 9 (2.8%) | 1 (2%) | 0 (0.0%) | 3 (5.5%) | 2 (6.5%) | 0 (0.0%) | 3 (6.7%) | 0 (0.0%) |
| Sp140 | 29 (15.2%) | 6 (1.9%) | 0 (0%) | 2 (4.7%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 2 (4.4%) | 1 (2.0%) |
| Newly identified PBC-related autoantigens | |||||||||
| HK1 isoform I | 89 (46.6%) | 33 (10.3%) | 0 (0%) | 3 (7.0%) | 2 (3.6%) | 0 (0.0%) | 11 (22.9%) | 13 (28.9%) | 4 (8.2%) |
| HK1 isoform II | 84 (44.0%) | 30 (9.3%) | 0 (0%) | 3 (7.0%) | 1 (1.8%) | 0 (0.0%) | 10 (20.8%) | 12 (26.7%) | 4 (8.2%) |
| KLHL12 | 77 (40.3%) | 16 (5.0%) | 0 (0%) | 7 (16.3%) | 2 (3.6%) | 0 (0.0%) | 1 (2.1%) | 1 (2.2%) | 5 (10.2%) |
| KLHL7 | 67 (35.1%) | 8 (2.5%) | 0 (0%) | 4 (9.3%) | 1 (1.8%) | 0 (0%) | 1 (2.1%) | 1 (2.2%) | 1 (2.0%) |
| ZBTB2 | 32 (16.8%) | 5 (1.6%) | 1 (2%) | 0 (0.0%) | 1 (1.8%) | 0 (0.0%) | 0 (0.0%) | 2 (4.4%) | 1 (2.0%) |
| EIF2C1 | 29 (15.2%) | 15 (4.7%) | 0 (0%) | 4 (9.3%) | 1 (1.8%) | 1 (3.2%) | 1 (2.1%) | 7 (15.6%) | 1 (2.0%) |
| NXN | 28 (14.7%) | 12 (3.7%) | 0 (0%) | 2 (4.7%) | 1 (1.8%) | 0 (0.0%) | 4 (8.3%) | 2 (4.4%) | 3 (6.1%) |
| RPS19 | 26 (13.6%) | 13 (4.0%) | 0 (0%) | 3 (7.0%) | 1 (1.8%) | 0 (0.0%) | 1 (2.1%) | 6 (13.3%) | 2 (4.1%) |
| ANXA10 | 25 (13.1%) | 3 (0.9%) | 0 (0%) | 1 (2.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (4.4%) | 0 (0.0%) |
| SNX9 | 22 (11.5%) | 3 (0.9%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (6.7%) | 0 (0.0%) |
| EIF4H | 21 (11.0%) | 11 (3.4%) | 0 (0%) | 2 (4.7%) | 1 (1.8%) | 1 (3.2%) | 0 (0.0%) | 5 (11.1%) | 2 (4.1%) |
| SPATA5 | 19 (9.9%) | 8 (2.5%) | 0 (0%) | 1 (2.3%) | 2 (3.6%) | 0 (0.0%) | 1 (2.1%) | 1 (2.2%) | 3 (6.1%) |
| ATCAY | 11 (5.8%) | 3 (0.9%) | 1 (2%) | 1 (2.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (2.0%) |
| DDX55 | 10 (5.2%) | 3 (0.9%) | 0 (0%) | 0 (0.0%) | 1 (1.8%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) | 1 (2.0%) |
| KEAP1 | 6 (3.1%) | 5 (1.6%) | 0 (0%) | 1 (2.3%) | 1 (1.8%) | 0 (0.0%) | 0 (0.0%) | 3 (6.7%) | 0 (0.0%) |
| TRA16 | 3 (1.6%) | 0 (0.0%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| IL1A | 1 (0.5%) | 3 (0.9%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 1 (3.2%) | 1 (2.1%) | 0 (0.0%) | 1 (2.0%) |
| DR1 | 0 (0.0%) | 1 (0.3%) | 1 (2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
a Non-PBC including healthy, AIH, HBV, HCV, RA, SLE, and SSc.